Evidence map›Paper›PMID 41091305›Full record

ReviewDiscover oncology2025

Emerging therapeutic advancements in pancreatic cancer: a contemporary review.

Midhun Malla, Yara Sakr, Garima Gupta, Mehmet Akce, Bassel El-Rayes

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Midhun MallaDivision of Hematology-Oncology, GI Medical Oncology, O'Neal Comprehensive Cancer Center, UAB Immunology Institute, UAB Heersink School of Medicine, University of Alabama, 1802 6th Avenue South, Birmingham, AL, 35294, USA. midhunmalla@uabmc.edu.
Yara SakrDivision of Hematology-Oncology, GI Medical Oncology, O'Neal Comprehensive Cancer Center, UAB Immunology Institute, UAB Heersink School of Medicine, University of Alabama, 1802 6th Avenue South, Birmingham, AL, 35294, USA.
Garima GuptaDivision of Hematology-Oncology, GI Medical Oncology, O'Neal Comprehensive Cancer Center, UAB Immunology Institute, UAB Heersink School of Medicine, University of Alabama, 1802 6th Avenue South, Birmingham, AL, 35294, USA.
Mehmet AkceDivision of Hematology-Oncology, GI Medical Oncology, O'Neal Comprehensive Cancer Center, UAB Immunology Institute, UAB Heersink School of Medicine, University of Alabama, 1802 6th Avenue South, Birmingham, AL, 35294, USA.
Bassel El-RayesDivision of Hematology-Oncology, GI Medical Oncology, O'Neal Comprehensive Cancer Center, UAB Immunology Institute, UAB Heersink School of Medicine, University of Alabama, 1802 6th Avenue South, Birmingham, AL, 35294, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The escalating global burden of pancreatic ductal adenocarcinoma (PDAC) is imposing a critical health burden as a major cause of cancer-related mortality. Survival rates are low due to late-stage diagnosis and complex tumor microenvironments. The review discusses the multifaceted approach required for effective management, including the latest therapeutic approaches, and highlights the critical role of the tumor microenvironment in therapy response. Innovations in targeted therapies and immunotherapies are emphasized, with a focus on genetic mutations such as BRCA and KRAS that influence treatment outcomes. Furthermore, the article explores emerging therapeutic strategies, including the utilization of novel drug combinations. The review underscores the necessity for ongoing research to improve diagnostic techniques, develop more effective therapies, and ultimately enhance patient outcomes in pancreatic cancer.

Identifiers

PMID41091305
PMCPMC12528555

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.